Since the anti-PD-1 treatment during DC maturation resulted in increased DC survival, the approach of combining PDT and a method that blocks the PD-1/PD-L1 axis could therefore be an attractive improvement on the hitherto suboptimal results of glioma dendritic cell therapy [204,210]. This evidence concerns the gene PDCD1 and glioma.